Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
30
5
7
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
13.3%
4 terminated/withdrawn out of 30 trials
81.0%
-5.5% vs industry average
3%
1 trials in Phase 3/4
18%
3 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (30)
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Role: lead
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Role: lead
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Role: lead
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Role: lead
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Role: collaborator
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Role: lead
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb
Role: lead
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Role: lead
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Role: lead
DETERMINATION OF THE CELL OF ORIGIN (COO) in LDCGB
Role: lead
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
Role: collaborator
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
Role: lead
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
Role: collaborator
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
Role: lead
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
Role: lead
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Role: lead
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Role: lead
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Role: lead
Cyclosporine Plus Methotrexate or Alemtuzumab
Role: lead
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL
Role: lead